Related Experiment Video
Updated: Oct 3, 2025
07:32
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.5K
Prognostic Significance of the Systemic Immune-Inflammation Index (SII) in Patients With Small Cell Lung Cancer: A
Yuting Zhou1, Menglu Dai1, Zongxin Zhang1
1Clinical Laboratory, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, China.
Frontiers in Oncology
|February 21, 2022
Summary
The systemic immune-inflammation index (SII) is a significant prognostic indicator for overall survival in small cell lung cancer (SCLC). High SII is linked to worse outcomes and extensive-stage disease in SCLC patients.
Area of Science:
- Oncology
- Immunology
Background:
- Investigating the prognostic value of the systemic immune-inflammation index (SII) in small cell lung cancer (SCLC).
- Addressing inconsistencies in previous studies regarding SII's prognostic value in SCLC.
- Evaluating the clinicopathological significance of SII in SCLC.
Approach:
- Conducted a comprehensive meta-analysis of studies from PubMed, Web of Science, Embase, Cochrane Library, and CNKI.
- Calculated pooled hazard ratios (HRs) and 95% confidence intervals (CIs) for survival outcomes.
- Used combined odds ratios (ORs) and 95% CIs to assess correlations with clinicopathological features.
Key Points:
- A high SII was significantly associated with worse overall survival (OS) in SCLC patients (HR=1.52, p=0.003).
- High SII was linked to extensive-stage SCLC (OR=2.43, p<0.001).
- No significant correlation was found between SII and age, sex, smoking history, KPS, or initial therapeutic response.
Conclusions:
- The systemic immune-inflammation index (SII) serves as an effective prognostic indicator for OS in SCLC.
- Recommends utilizing SII for predicting OS in SCLC patients.
- Suggests combining SII with other biomarkers for optimized clinical strategies and personalized treatment selection.
